Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST)
Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) are guidelines to asses tumors that makes use of positron emission tomography (PET) to provide functional information to help determine tumor viability.
The criteria consist of four categories: complete metabolic response (CMR), partial metabolic response (PMR), progressive metabolic disease (PMD), and stable metabolic disease (SMD).
As used below, SUL is the standardized uptake value corrected for lean body mass. SULpeak (or SULpeak) is the peak SUL in a spherical 1 cm3 volume of interest (VOI).
Complete metabolic response (CMR)
- complete resolution of 18F-FDG uptake within the measurable target lesion
- so that it is less than mean liver activity
- so that it is at the level of surrounding background blood pool activity
- disappearance of all other lesions to background blood pool levels
- no new suspicious 18F-FDG avid lesions
- if progression according to RECIST criteria, must verify with follow up
Partial metabolic response (PMR)
- reduction of a minimum of 30% in target measurable tumor 18F-FDG SUL peak, with absolute drop in SUL of at least 0.8 SUL units
- no increase >30% of SUL or size in all other lesions
- no new lesions
Stable metabolic disease (SMD)
- no CMR, PMR, or progressive metabolic disease (PMD)
- no new lesions
Progressive metabolic disease (PMD)
- >30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumor SUL from the baseline scan in pattern typical of tumor and not of infection/treatment effect
- or visible increase in the extent of 18F-FDG tumor uptake
- or new 18F-FDG avid lesions typical of cancer and not related to treatment effect and/or infection
- 1. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. (2013) Radiographics : a review publication of the Radiological Society of North America, Inc. 33 (5): 1323-41. doi:10.1148/rg.335125214 - Pubmed